Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs, Proceedings of the National Academy of Sciences, vol.106, issue.20, pp.8192-8199, 2009. ,
DOI : 10.1073/pnas.0811919106
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy, Antimicrob Agents Chemother, vol.44, pp.2475-84, 2000. ,
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase., Antimicrobial Agents and Chemotherapy, vol.37, issue.10, pp.2231-2235, 1993. ,
DOI : 10.1128/AAC.37.10.2231
Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies, AIDS, vol.23, pp.455-60, 2009. ,
Characterization and structural analysis of HIV-1 integrase conservation, AIDS Rev, vol.11, pp.17-29, 2009. ,
Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors, Journal of Virology, vol.78, issue.8, pp.4234-4281, 2004. ,
DOI : 10.1128/JVI.78.8.4234-4247.2004
Umbruchvorlage 06.11, pp.51-52, 2009. ,
HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy, Science, vol.267, issue.5197, pp.483-492, 1995. ,
DOI : 10.1126/science.7824947
In vivo emergence of HIV-1 variants resistant to multiple
protease inhibitors, Nature, vol.374, issue.6522, pp.569-71, 1995. ,
DOI : 10.1038/374569a0
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection, N Engl J Med, vol.359, pp.355-65, 2008. ,
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation, Nucleic Acids Research, vol.37, issue.4, pp.1193-201, 2009. ,
DOI : 10.1093/nar/gkn1050
Raltegravir is effective in HIV-1 group O infected patients. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention:Cape Town, 2009. ,
Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier, Journal of Virology, vol.81, issue.24, pp.13845-51, 2007. ,
DOI : 10.1128/JVI.01184-07
Defining the DNA Substrate Binding Sites on HIV-1 Integrase, Journal of Molecular Biology, vol.385, issue.2, pp.568-79, 2009. ,
DOI : 10.1016/j.jmb.2008.10.083
Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction, The EMBO Journal, vol.17, issue.19, pp.5832-5875, 1998. ,
DOI : 10.1093/emboj/17.19.5832
The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy, AIDS, vol.23, issue.16, pp.2159-64, 2009. ,
DOI : 10.1097/QAD.0b013e32832ec4ae
Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations, Journal of Virology, vol.77, issue.21, pp.11459-70, 2003. ,
DOI : 10.1128/JVI.77.21.11459-11470.2003
Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways, Journal of Virology, vol.83, issue.22, pp.11440-11446, 2009. ,
DOI : 10.1128/JVI.01168-09
Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic Failure, Antimicrobial Agents and Chemotherapy, vol.53, issue.10, pp.4522-4526, 2009. ,
DOI : 10.1128/AAC.00651-09
Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes, The EMBO Journal, vol.20, issue.13, pp.3565-76, 2001. ,
DOI : 10.1093/emboj/20.13.3565
The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral, Antimicrobial Agents and Chemotherapy, vol.52, issue.3, pp.901-909, 2008. ,
DOI : 10.1128/AAC.01218-07
Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors, Journal of Virology, vol.82, issue.21, pp.10366-74, 2008. ,
DOI : 10.1128/JVI.00470-08
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase, Proceedings of the National Academy of Sciences, vol.101, issue.31, pp.11233-11241, 2004. ,
DOI : 10.1073/pnas.0402357101
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells, Science, vol.287, issue.5453, pp.646-50, 2000. ,
DOI : 10.1126/science.287.5453.646
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature, vol.176, issue.6510, pp.123-129, 1995. ,
DOI : 10.1038/373123a0
Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking, The EMBO Journal, vol.16, issue.22, pp.6849-59, 1997. ,
DOI : 10.1093/emboj/16.22.6849
Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase, Antimicrobial Agents and Chemotherapy, vol.53, issue.3, pp.1194-203, 2009. ,
DOI : 10.1128/AAC.00984-08
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease., Proceedings of the National Academy of Sciences, vol.91, issue.12, pp.5597-601, 1994. ,
DOI : 10.1073/pnas.91.12.5597
Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants, Antiviral Research, vol.80, issue.2, pp.213-235, 2008. ,
DOI : 10.1016/j.antiviral.2008.06.012
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, The Lancet, vol.374, issue.9692, pp.796-806, 2009. ,
DOI : 10.1016/S0140-6736(09)60918-1
Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors, Antimicrobial Agents and Chemotherapy, vol.53, issue.10, pp.4275-82, 2009. ,
DOI : 10.1128/AAC.00397-09
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients, Journal of Antimicrobial Chemotherapy, vol.63, issue.4, pp.795-804, 2009. ,
DOI : 10.1093/jac/dkp014
Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro, Antimicrobial Agents and Chemotherapy, vol.52, issue.4, pp.1351-1359, 2008. ,
DOI : 10.1128/AAC.01228-07
Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug, Journal of Virology, vol.74, issue.18, pp.8524-8555, 2000. ,
DOI : 10.1128/JVI.74.18.8524-8531.2000
Molecular basis of human immunodeficiency virus drug resistance: An update, Antiviral Research, vol.85, issue.1, 2009. ,
DOI : 10.1016/j.antiviral.2009.07.006
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations, Cell, vol.58, issue.5, pp.901-911, 1989. ,
DOI : 10.1016/0092-8674(89)90942-2
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nature Medicine, vol.69, issue.7, pp.760-766, 1996. ,
DOI : 10.1016/S0140-6736(95)90699-1
HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations, Journal of Molecular Recognition, vol.52, issue.21, pp.480-94, 2009. ,
DOI : 10.1177/108705710275212
URL : https://hal.archives-ouvertes.fr/hal-00811679
Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 Integrase, Journal of Virology, vol.82, issue.18, pp.9228-9263, 2008. ,
DOI : 10.1128/JVI.01535-07
Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics, Antiviral Res, vol.81, pp.141-147, 2009. ,
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time, Science, vol.271, issue.5255, pp.1582-1588, 1996. ,
DOI : 10.1126/science.271.5255.1582
Parameters Driving the Selection of Nelfinavir-Resistant Human Immunodeficiency Virus Type 1 Variants, Journal of Virology, vol.77, issue.18, pp.10172-10177, 2003. ,
DOI : 10.1128/JVI.77.18.10172-10175.2003
Fidelity of HIV-1 reverse transcriptase, Science, vol.242, issue.4882, pp.1168-71, 1988. ,
DOI : 10.1126/science.2460924
Selective-Advantage Profile of Human Immunodeficiency Virus Type 1 Integrase Mutants Explains In Vivo Evolution of Raltegravir Resistance Genotypes, Journal of Virology, vol.83, issue.19, pp.10245-10254, 2009. ,
DOI : 10.1128/JVI.00894-09
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy, J Virol, vol.68, pp.1660-1666, 1994. ,
The accuracy of reverse transcriptase from HIV-1, Science, vol.242, issue.4882, pp.1171-1174, 1988. ,
DOI : 10.1126/science.2460925
Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity, Journal of Clinical Virology, vol.46, issue.2, pp.173-178, 2009. ,
DOI : 10.1016/j.jcv.2009.06.020
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors, Retrovirology, vol.6, issue.1, p.25, 2009. ,
DOI : 10.1186/1742-4690-6-25
Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137), Journal of Virology, vol.82, issue.2, pp.764-74, 2008. ,
DOI : 10.1128/JVI.01534-07
Evolution of raltegravir resistance during therapy, Journal of Antimicrobial Chemotherapy, vol.64, issue.1, pp.25-32, 2009. ,
DOI : 10.1093/jac/dkp153
Raltegravir with optimized background therapy for resistant HIV-1 infection, N Engl J Med, vol.359, pp.339-54, 2008. ,
S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention:Cape Town, 2009. ,
Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility, AIDS, vol.22, issue.14, pp.1877-80, 2008. ,
DOI : 10.1097/QAD.0b013e32830f9703
TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments, Journal of Virology, vol.79, issue.20, pp.12773-82, 2005. ,
DOI : 10.1128/JVI.79.20.12773-12782.2005
Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry, Journal of Virology, vol.81, issue.5, pp.2359-71, 2007. ,
DOI : 10.1128/JVI.02006-06
Genetic Diversity of Integrase (IN) Sequences in Antiretroviral Treatment-Naive and Treatment-Experienced HIV Type 2 Patients, AIDS Research and Human Retroviruses, vol.24, issue.7, pp.1003-1010, 2008. ,
DOI : 10.1089/aid.2007.0303
Inserm U941 Institut Universitaire d'Hématologie Hôpital Saint-Louis Paris France E-mail: francois.clavel@inserm, fr EUROPEAN JOURNAL OF MEDICAL RESEARCH, vol.54, 2009. ,